Bioventures 2014 L.P. Mpm Sells 14,569 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the completion of the sale, the insider owned 4,318,348 shares of the company’s stock, valued at approximately $30,487,536.88. The trade was a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Tuesday, August 25th, Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88.
• On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.34, for a total transaction of $158,712.82.

Entrada Therapeutics Stock Up 3.9%

Shares of NASDAQ TRDA opened at $7.27 on Friday. Entrada Therapeutics, Inc. has a 52-week low of $5.02 and a 52-week high of $16.45. The firm has a fifty day moving average of $7.09 and a 200-day moving average of $9.33. The stock has a market capitalization of $283.07 million, a PE ratio of -1.84 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $0.90 million for the quarter, compared to analyst estimates of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. Equities research analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TRDA shares. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Roth Capital reissued a “buy” rating and set a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Guggenheim decreased their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Finally, Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Entrada Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $17.75.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Odyssean LLC acquired a new stake in Entrada Therapeutics during the 2nd quarter worth about $230,000. Nantahala Capital Management LLC purchased a new position in shares of Entrada Therapeutics in the second quarter worth approximately $2,212,232,000. Public Employees Retirement System of Ohio purchased a new position in shares of Entrada Therapeutics in the second quarter worth approximately $276,000. Bank of America Corp DE acquired a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $426,000. Finally, 5AM Venture Management LLC acquired a new stake in shares of Entrada Therapeutics during the second quarter valued at approximately $29,854,949,000. 86.39% of the stock is owned by institutional investors and hedge funds.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.